

¹**Assortative mating and parental genetic relatedness drive the** ²**pathogenicity of variably expressive variants**

3

- 25 8. Department of Medical Genetics, University and University Hospital Antwerp, Antwerp,
- 26 Belgium.
- 27 9. Greenwood Genetic Center, Greenwood, SC 29646, USA.
- 28 10. Centre de Genetique et Cenre de Référence Anomalies du développement et syndromes 29 malformatifs, Hôpital d'Enfants, CHU Dijon, Dijon, France.
- 30 11. GAD INSERM UMR1231, FHU TRANSLAD, Université de Bourgogne Franche Comté, Dijon, 31 France
- 32 12. Laboratoire de Genetique Chromosomique et Moleculaire, CHU Dijon, France.
- 33 13. Department of Paediatrics, University of Melbourne, Melbourne, Australia.
- 34 14. Bruce Lefroy Center, Murdoch Children's Research Institute, Melbourne, Australia
- 35 15. Research Unit of Rare Diseases and Neurodevelopmental Disorders, Oasi Research Institute-36 IRCCS, 94018 Troina, Italy
- 37 16. Medical Genetics, Department of Biomedical and Biotechnological Sciences, University of 38 Catania, 95123 Catania, Italy.
- 39 17. Medical Genetics, ASP Ragusa, Ragusa, Italy.
- 40 18. CHU Nantes, Department of Medical Genetics, Nantes, France.
- 41 19. CHU Toulouse, Department of Medical Genetics, Toulouse, France
- 42 20. ToNIC, Toulouse Neuro Imaging, Center, Inserm, UPS, Université de Toulouse, Toulouse, 43 France
- 44 21. Service de Cytogenetique, CHU de Le Mans, Le Mans, France.
- 45 22. Department of Genetics, Bretonneau University Hospital, Tours, France.
- 46 23. Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.
- 47 24. Department of Clinical Genetics, Amsterdam UMC, Amsterdam, The Netherlands.
- 48 25. Department of Anthropology, Pennsylvania State University, University Park, PA 16802, USA.
- 49 *Correspondence: sxg47@psu.edu

50 **ABSTRACT**

70 **INTRODUCTION**

71 Rare genomic variants, including copy-number variants (CNVs) and single nucleotide variants (SNVs), 72 contribute to a significant proportion of individuals with neurodevelopmental and psychiatric disorders^{1–} 73 \textdegree . Many of these variants are often inherited and exhibit variable expressivity and phenotypic heterogeneity, in contrast to syndromic variants with invariable clinical presentation⁸. For example, 75 phenotypic heterogeneity has been observed among carriers of rare recurrent SNVs associated with 16 neurodevelopmental disorders⁹, such as the candidate schizophrenia gene *NRXN1*, which also 77 contributes to intellectual disability/developmental delay (ID/DD), autism, and congenital 78 malformations with varying degrees of penetrance¹⁰. This variable expressivity and phenotypic 79 heterogeneity can be attributed to a multi-hit model, where a primary variant sensitizes the genome for 80 neuropsychiatric features and genetic interactions of the primary variant with other ("secondary") 81 variants in the genetic background determine the ultimate phenotypic outcome^{11–14}. In fact, pathogenic 82 rare CNVs on chromosome 1q21.1, 15q13.3, and 16p12.1 tend to be transmitted from a relatively mildly 83 affected parent, with the increase in phenotypic severity corresponding to an increase in the number (i.e. 84 burden) of secondary variants over generations^{11,14,15}. These secondary variants are often inherited from 85 the non-carrier parent and have been shown to act synergistically with the primary pathogenic 86 variant^{14,16}. This phenomenon of complex inheritance forms the basis of many neurodevelopmental 87 disorders and complicates predicting the phenotypic trajectory of individuals within families with these 88 disorders.

89 These complexities necessitate examining other factors, such as parental phenotype and 90 genotype, in affected probands that may elucidate their ultimate phenotypic trajectory. Previous reports 91 have shown that family history is a risk factor for neurodevelopmental disorders, with increased within 92 and cross-disorder risk observed among relatives of individuals with psychiatric disease $17-19$. This 93 increase in liability towards multiple diagnostic outcomes may be due to the overlapping genetic

- 94 etiologies of neurodevelopmental disorders²⁰ and is particularly relevant for understanding mechanisms 95 of variable expressivity of rare variants. Here, we sought to broaden our understanding of the effect of 96 various phenotypic and genetic factors in parents on neurodevelopmental disease outcomes in children. 97 To that end, we examined more than 38,000 spouse pairs and parent pairs of children with 98 neurodevelopmental disorders to identify risk factors that affect disease trajectories in affected children, 99 including clinical and subclinical neurological and psychiatric features and patterns of assortative mating 100 on those features, as well as genetic similarity between parents. We further investigated the implications 101 of these patterns across generations and identified potential mechanisms by which they contribute to 102 disease risk. Our findings highlight assortative mating and parental kinship as previously unexplored
- 103 risk factors for neurodevelopmental and neuropsychiatric disease.

104 **SUBJECTS AND METHODS**

105 **Cohort Information**

106 We assessed parental factors affecting neurodevelopmental disease in two North American autism 107 cohorts: the Simons Simplex Collection $(SSC)^{21}$ and the Simons Foundation Powering Autism Research 108 (SPARK)²². We analyzed genetic and/or phenotypic data from 2,517 trios from SSC and 7,175 trios 109 from SPARK. We also analyzed genetic and/or phenotypic data from an additional 67 parent pairs in 110 SSC and 1,570 parent pairs in SPARK for families where the relevant proband data were not available. 111 We also collected genomic and/or phenotypic data for another neurodevelopmental disease 112 cohort of 203 samples from 43 trios, 4 larger families, and 21 spouse pairs carrying the 16p12.1 113 deletion. Probands in these families were ascertained for developmental delays or other 114 neurodevelopmental phenotypes and were identified as 16p12.1 deletion carriers through clinical 115 diagnostic tests. Families provided informed consent to give blood samples and phenotypic data under 116 Pennsylvania State University Institutional Review Board approved protocol #STUDY00000278, and 117 deidentified data from medical reports were collected under approved protocol #STUDY00017269. 118 We further assessed assortative mating and spousal relatedness in 26,610 partner pairs from the 119 UK Biobank²³, identified using Data Return 1872^{24} (Application ID: 45023). UK Biobank is a database 120 containing genetic, lifestyle, and health information from 500,000 volunteer participants from the UK. 121 Additionally, we assessed profiles of genetic relatedness in parent pairs of children ascertained for 122 neurodevelopmental disorders carrying rare copy number variants (CNVs) from another clinical cohort 123 evaluated at GeneDx. This cohort consists of families with affected children referred by clinicians to 124 GeneDx for genetic testing and is distinct from the 16p12.1 deletion cohort. Families were subsequently 125 selected for those carrying pathogenic CNVs (see *CNV calling*), resulting in 357 parent pairs from 126 families carrying 21 distinct disease-associated CNVs (**Supp. Table 1**). The study of this cohort was 127 conducted under an IRB protocol approved by the Western Institutional Review Board (IRB #STUDY

131

132 **DNA Extraction and Sequencing**

133 DNA extraction and sequencing of samples within the SPARK, SSC, and UK Biobank cohorts were

134 performed by the relevant biobank. For directly recruited participants from the 16p12.1 deletion cohort,

135 DNA was extracted from peripheral blood using the QIAamp DNA Blood Maxi extraction kit (Cat. No:

136 51104, Qiagen), while clinical collaborators sent DNA samples directly to the Girirajan laboratory. SNP

137 arrays for 36 samples were generated as previously described¹⁴, while 92 additional samples were run on

138 Illumina OmniExpress 24 v 1.1 microarrays at the Northwest Genomics Center at the University of

139 Washington (Seattle, WA, USA). Illumina HiSeq X was used to generate 150-bp paired-end whole

140 genome sequence (WGS) data at ≥30X coverage for 118 individuals by Macrogen Labs (Rockville, MD,

141 USA). DNA extraction and sequencing from the GeneDx cohort were performed as previously

142 described²⁵.

143

144 **Variant calling**

145 *CNV calling*: CNVs in the GeneDx cohort were first called from exome sequencing data and confirmed

146 via microarray, as previously described²⁵. Disease-associated CNVs were identified from any overlap

147 with previously reported breakpoints for pathogenic $CNVs^{15}$.

148 *SNV calling*: Single nucleotide variants (SNVs) and small indels were identified in 16p12.1 deletion

149 families using the GATK Best Practices pipeline. After removing duplicates with PicardTools²⁶, we

150 performed base-pair quality score recalibration and then used GATK HaplotypeCaller v.3.8²⁷ to call

151 variants. Calls from all samples were merged to call variants jointly using GATK GenotypeGVCFs

- 152 $v.4.0.11^{27}$, followed by variant quality score recalibration. Variants were filtered for those with an allele
- 153 balance between 0.25 and 0.75 or >0.9 and a read depth of \geq 8.
- 154 Whole genome (for SSC) and whole exome (for SPARK) variant call files (VCFs) were
- 155 downloaded from SFARI Base (https://base.sfari.org). Whole exome VCFs were obtained from the UK
- 156 Biobank using Data Field 23157. VCFs from all three cohorts were left-normalized and multi-allelic
- 157 records were split with BCFtools²⁸. Calls were filtered using the same criteria as above. Variants from
- 158 the 16p12.1 deletion cohort, SSC, and SPARK were additionally filtered for a quality ≥50 and a ratio of
- 159 quality to alternative allele depth \geq 1.5.
- 160 For all four cohorts, variant frequency in gnom AD^{29} was annotated using vcfanno³⁰ and variants
- 161 were filtered for those with gnomAD exome and genome frequency ≤0.1%. Variants in the SSC,
- 162 SPARK, and UK Biobank cohorts were filtered for an intracohort frequency ≤0.1%. To achieve a
- 163 similar frequency threshold with a smaller sample size, variants in the 16p12.1 deletion cohort were
- 164 filtered for those that were private within related individuals. ANNOVA R^{31} was used to assign variants
- 165 to genes from GENCODE v19 (16p12.1 deletion cohort) or GENCODE v38 (SSC, SPARK, and UK
- 166 Biobank)³², and variants in all cohorts were filtered for loss-of-function (LOF), missense, or splice
- 167 variants in protein-coding genes. LOF variants were those annotated as 'stopgain', 'stoploss',
- 168 'frameshift deletion', 'frameshift insertion', or 'frameshift substitution' by ANNOVAR, and missense
- 169 variants were those annotated as 'nonsynonymous_SNV', 'nonframeshift_deletion',
- 170 'nonframeshift insertion', or 'nonframeshift substitution'. CADD Phred-like scores³³ were annotated
- 171 using vcfanno as a deleteriousness metric and missense and splice variants were filtered for those with a
- 172 CADD Phred score ≥25. For probands within SSC, variants were additionally annotated with SFARI
- 173 Gene Tier of the affected gene³⁴.
- 174 *Polygenic risk score calculations:* We obtained autism GWAS summary statistics from Grove and
- 175 colleagues³⁵. Duplicate and ambiguous single nucleotide polymorphisms (SNPs) were removed, and the
- 176 remaining SNPs were filtered for imputation INFO scores > 0.8 . We then used PLINK³⁶ to perform an

190

191 **Phenotype Assessment**

192 We assessed self-reported psychiatric phenotypes in probands and parents in the SPARK cohort and 23 193 quantitative autism and cognitive metrics in probands (**Supp. Table 2**) and two quantitative autism 194 metrics in parents (Social Responsiveness Scale (SRS)⁴⁰ and Broad Autism Phenotype Questionnaire (BAPQ)⁴¹) from the SSC cohort downloaded from SFARI base (https://base.sfari.org). We further 196 assessed neurological and psychiatric phenotypes in 57 parent pairs from 16p12.1 deletion families. 197 Information was collected on each adult family member either through self-reports using a standardized 198 clinical questionnaire or clinician reports. Curated data was generated using a union of clinical 199 diagnoses, self-reported phenotypes, and interpreted responses to clinical questionnaires. We also 200 assessed phenotypic correlations in the UK Biobank using self-reported diagnoses of psychiatric 201 disorders from Data Field 20544.

202 Linear regression was used to assess the predictive power of parental SRS and BAPQ scores and 203 various genetic factors, including autism PRS and rare CNVs and SNVs, towards child quantitative 204 phenotypes, while tetrachoric correlations were used to assess phenotypic correlations between 205 psychiatric diagnoses in parents and children and between spouse pairs. To minimize the effects of 206 comorbidities and isolate the specific correlations of interest, pairs were removed from cross-disorder 207 tetrachoric correlations if both members of the pair had either diagnosis of interest. For example, when 208 examining the relationship between the female member of the spouse pair having anxiety and their 209 partner having depression, pairs where the male partner had anxiety or the female partner had depression 210 were excluded from the analysis.

211

212 **Kinship Calculations**

213 In the 16p12.1 deletion, SSC, SPARK, and UK Biobank cohorts, we followed the same initial SNP 214 quality control steps outlined above for PRS calculations. Additionally, SNPs within long-range linkage 215 disequilibrium regions⁴² were removed, as were samples with ± 2 standard deviations of the mean cohort 216 heterozygosity rate. For SPARK, SSC, and the 16p12.1 cohort samples, we next assessed ancestry using 217 fastStructure⁴³ to cluster samples (k=5-6) against individuals with known ancestry from the HapMap3 218 project³⁸. Kinship analysis in these cohorts was restricted to pairs with self-reported or calculated 219 European ancestry. UK Biobank samples were filtered for pairs of European ancestry using Data Field 220 22006.

221 KING⁴⁴ was used to calculate kinship coefficients for 44 parent pairs from the 16p12.1 cohort, 222 1,996 parent pairs from the SSC cohort, 4,211 parent pairs from the SPARK cohort, 6,315 partner pairs 223 from the UK Biobank cohort, and 357 parent pairs from the GeneDx cohort. In the GeneDx cohort, 11 224 parent pairs with a kinship coefficient less than -0.1 were removed from further analysis, as this highly 225 negative value may indicate that these samples come from different ancestral populations.

226

10

227 **Runs of Homozygosity**

- 228 To identify runs of homozygosity (ROH), we applied the same initial SNP quality control filters
- 229 described above for PRS calculations on 3,714 probands ascertained for autism in the SPARK cohort
- 230 and 1,981 probands from the SSC cohort. ROHs were calculated using the PLINK *homozyg* function³⁶.
- 231 We allowed a maximum of one heterozygous and five missing SNPs in each ROH, and runs were
- 232 restricted to those at least 1 Mbp in length.
- 233

234 **Statistical Analysis**

- 235 Tetrachoric correlations were performed using the *correlation* package⁴⁵ in R. Linear regression was
- 236 performed using *statsmodels* in Python, with proband age at the time the Autism Diagnostic Observation
- 237 Schedule (ADOS) was administered included as a covariate in the models. Pearson correlations and t-
- 238 tests were performed using the *pearsonr* and *ttest ind* functions in the *scipy stats* (v. 1.7.1) package⁴⁶ in
- 239 Python (v. 3.9.7), respectively.

240 **RESULTS**

241 **Parental phenotypes predict child phenotypes**

242 To understand the relevance of parental phenotypes in neurodevelopmental disorders, we examined the 243 correlation between six parent and child psychiatric phenotypes in the Simons SPARK autism cohort 244 (**Fig. 1A, Table S4A**). We observed significant positive within-disorder correlations between mothers 245 and fathers and male and female probands for most phenotypes (Pearson correlation, R=0.1-0.49, 246 Bonferroni-corrected p<0.05) (**Fig. 1A, Table S4A**). We also observed several cross-disorder 247 correlations, including those common to both sexes, such as the correlation between depression in 248 parents and anxiety in probands $(R=0.10-0.27, p<0.01)$, and those which are unique to one sex, such as 249 the correlation between OCD in fathers and ADHD in female probands $(R=0.13, p=0.003)$, suggesting 250 parental and sex-specific correlations for certain pairs of features (**Fig. 1A, Table S4A**). These 251 correlations recapitulate previous patterns of within- and cross- disorder correlations observed in studies 252 of both psychiatric disease cohorts and cohorts from the general population^{17,47,48}. 253 To assess the relationship of parent and child phenotypes outside the context of a family history 254 of psychiatric disorders, we used linear models to assess the relationship between 23 quantitative

255 measures of autism and cognitive features (**Table S2**) in probands from the simplex autism cohort SSC

256 and two measures of autism features in their unaffected parents, Social Responsiveness Scale $(SRS)^{40}$

257 and Broad Autism Phenotype Questionnaire (BAPQ)⁴¹ scores (**Fig. 1B, Table S4B**). Several measures

258 of autism features in probands were significantly influenced by parental SRS scores, including

259 Repetitive Behaviors Scale (RBS)⁴⁹ (β =0.14, Bonferroni-corrected p=1.95×10⁻⁶), SRS (β =0.11,

260 p=0.002), and Child Behavior Checklist (CBCL)⁵⁰ internalizing (β =0.15, p=1.11×10⁻⁵) scores of

261 children with autism were positively associated with biparental mean SRS scores (**Fig. 1B, Table S4B**).

262 Biparental mean SRS and/or BAPQ scores were in fact stronger predictors of autism severity in affected

263 children than any individual group of rare or common genetic variants for several measures (**Fig. 1B,**

Figure 1. Parental phenotypes predict clinical outcomes in children.

(A) Tetrachoric correlations between self-reported psychiatric disorders in mothers and fathers and male and female probands within the SPARK autism cohort (n=592-4,757 for each correlation). (B) Regression coefficients from linear models incorporating effects of both genetic factors and parental phenotypes towards quantitative proband autism and cognitive phenotypes (n=1,628-2,168 for each model). RBS: Repetitive Behaviors Scale, SRS: Social Responsiveness Scale, CBCL int: Child Behavior Checklist 6-18 internalizing, FSIQ: Fullscale IQ. Selected models shown here, full data in Table S4. Blue dots and lines indicate significance after Bonferroni-correction. * Bonferroni-corrected p≤0.05, ** p≤0.01, *** p≤0.001.

13

264 **Table S4B**). These data highlight the potential utility of assessing parent phenotypes to predict child 265 phenotypes. Even in simplex families, where parents are largely unaffected, child phenotypes can be 266 predicted by parent phenotypes, suggesting some sub-clinical level of genetic liability in the parents of 267 affected children which compounds within a single generation to surpass a disease threshold. This also 268 indicates the presence of multiple genetic factors which individually are not sufficient to cause overt 269 phenotypes in parents but may additively or synergistically interact in offspring to cause more overt 270 phenotypes in subsequent generations.

271

272 **Phenotypic assortment among partner pairs**

273 Given the relevance of parental phenotypes towards predicting phenotypes in affected children, we 274 hypothesized that assortative mating may be a relevant risk factor for neurodevelopmental disease. 275 Assortative mating has been well described for neurological and psychiatric phenotypes^{24,51–58} and has 276 previously been shown to result in increasing disease liability over generations using national registrar 277 data from Sweden and Denmark^{17,47,59}. This is akin to patterns of increasing disease liability observed in 278 neurodevelopmental disease cohorts, particularly in families carrying variably expressive variants $11,14,15$. 279 Using the 16p12.1 deletion as a paradigm for these disorders, we first examined the frequency of self-280 reported neurological and psychiatric features in adult family members of children with the 16p12.1 281 deletion ascertained for neurodevelopmental phenotypes. Adult deletion carriers in our cohort 282 manifested several neurological and psychiatric phenotypes, including seizures (5.8%), schizophrenic 283 features (20%), depression (36%) and anxiety (39%) symptoms, and addiction phenotypes (8.0%) (**Fig.** 284 **2A**). In line with expectations of assortative mating, their non-carrier partners also manifested these 285 features at similar frequencies (seizure: 5.8%, schizophrenic features: 12%, depression: 28%, anxiety: 286 26%, addiction: 10%) (**Fig. 2A**). As these data are indicative of assortative mating, we further assessed 287 spousal assortment based on these phenotypes and were able to identify several significant within- and 288 cross-disorder correlations (**Fig. 2B, Table S4C**). For example, 16p12.1 deletion carriers with anxiety

14

(A) Percentage of carrier and non-carrier spouses in a cohort of 16p12.1 deletion carrier families with five neurological and psychiatric disorders (n=49-52). (B-D) Tetrachoric correlations of neurological and psychiatric phenotypes between (B) carrier and non-carrier spouses in the 16p12.1 deletion cohort (n=28-50), (C) mothers and fathers in the SPARK autism cohort (n=3,956-6,142), and (D) female and male spousal partners in the UK Biobank (n=19,468-22,953). Grey boxes indicate insufficient sample size for correlation. * Bonferroni-corrected p≤0.05, ** p≤0.01, *** p≤0.001.

289 were likely to have partners with anxiety (R=0.69, Bonferroni-corrected $p=8.14\times10^{-7}$) or depression 290 (R=0.66, p=0.001) (**Fig. 2B, Table S4C**). These data confirm that the well-documented patterns of 291 assortative mating for psychiatric phenotypes are typically prevalent in families carrying variably 292 expressive variants with a high load of genetic liability for neurodevelopmental disorders. We also 293 compared patterns of phenotypic assortment in parents of children in an affected cohort and the general 294 population by analyzing five self-reported psychiatric phenotypes in the SPARK autism cohort and the 295 UK Biobank (**Fig. 2C-D, Table S4D**). Although these phenotypes occur much more frequently in the 296 SPARK cohort (**Supp. Table 3**), positive within- and cross- disorder correlations were observed in both 297 of these cohorts (**Fig. 2C-D, Table S4D**). For example, women in both cohorts with bipolar disorder or 298 mania were more likely to have partners with bipolar disorder (SPARK: R=0.30, Bonferroni-corrected 299 p=7.69×10⁻¹²⁹; UKB: R=0.24, p=3.53×10⁻³⁰⁴) or schizophrenia (SPARK: R=0.24, p=3.90×10⁻⁸⁰; UKB: 300 R=0.50, p=0) (**Fig 2C-D**). This confirms that spousal assortment on psychiatric phenotypes occurs both 301 in individuals ascertained for disease and those from the general population.

302

303 **Genetic consequences of assortative mating**

304 Partner assortment will result in positive correlations between their risk alleles, which underly the 305 phenotypes driving assortment⁶⁰. While genetic risk of assortative mating is often measured using 306 association studies of common variants^{24,60–62}, we hypothesized that rare deleterious variants also 307 correlate among partners, given the links between rare variants and psychiatric disorders on which 308 partners tend to assort^{7,63,64}. To confirm this pattern in the assessed cohorts, we correlated the burden of 309 rare deleterious coding single nucleotide variants (SNVs) between partners in each cohort (**Fig. 3A**). We 310 observed that the burden of rare variants positively correlated between partners in the 16p12.1 deletion 311 cohort (Pearson's R=0.46, p=2.79×10⁻⁴), SPARK (R=0.52, p<10⁻¹²), Simons Simplex Collection (SSC, $R=0.57$, $p<10^{-12}$), and the UK Biobank (R=0.07, $p=6.80\times10^{-9}$) cohorts (**Fig. 3A**), confirming that partner

Figure 3. Assortative mating drives increases in genetic risk variance.

(A) Pearson correlations of rare, likely deleterious SNVs in female and male partners of spouse pairs from the 16p12.1 deletion cohort (n=59), SPARK (n=7,352) and SSC (n=2,397) autism, and the UK Biobank (n=10,323) cohorts. (B) Schematic illustrating increases in disease liability variance over generations resulting from assortative mating. (C) Example pedigree of assortative mating and compounding

326

327 **Parental relatedness as a risk factor for neurodevelopmental disease**

328 Another parental factor which can increase disease risk is the level of consanguinity or genetic 329 relatedness of parents, through increasing both the frequency of autosomal recessive conditions and 330 genome-wide homozygosity^{66,67}. Long stretches of homozygosity have been associated with increased 331 risk for several neurodevelopmental disorders^{68,69}. Although the parents assessed in our cohorts are not 332 consanguineous, we hypothesized that increases in parental relatedness lead to increases in genome-333 wide homozygosity and increased risk of neurodevelopmental disorders. To assess this, we examined 334 large (≥1 Mbp) runs of homozygosity (ROH) in 3,714 and 1,981 children of the parent pairs analyzed in 335 the SPARK and SSC cohorts, respectively. We found a significant correlation between parental 336 relatedness (as measured by kinship coefficients) and the number of large ROH in both male and female

Figure 4. Parental relatedness correlates with homozygosity in children.

Pearson correlations of parental relatedness (measured as kinship coefficients) and the number of large (≥1 Mb) runs of homozygosity in male and female probands in the SSC (male n=1,711, female n=270) and SPARK (male n=2,956, female n=758) autism cohorts.

(A) Pearson correlations of the average burden of rare, likely deleterious variants and relatedness (measured as kinship coefficients) in spouse pairs from the 16p12.1 deletion (n=44), SPARK $(n=4,095)$ and SSC $(n=1,813)$ autism, and UK Biobank $(n=6,315)$ cohorts. (B) Comparison of parental relatedness among SSC probands with loss-of-function mutations in Tier S SFARI genes $(n=102)$ and without mutations in SFARI genes $(n=1,243)$. Lines indicate median. One tailed t-test. (C-E) Comparisons of parental relatedness among probands ascertained for neurodevelopmental disease with (C) *de novo* (n=129) and inherited (n=116) CNVs, (D) deletions (n=249) and duplications ($n=97$), and (E) syndromic ($n=47$) and variably expressive ($n=299$) CNVs. Lines indicate median. One tailed t-test.

373 **DISCUSSION**

374 Assortative mating has previously been hypothesized to explain the high degree of heritability for 375 complex neurodevelopmental and psychiatric disorders^{54,75}. However, the implications of assortative 376 mating have not been explored in the context of rare variably expressive pathogenic variants. Here, we 377 confirm that the well-documented patterns of spousal assortment on neuropsychiatric features $24,51-58$ 378 hold true for families carrying rare disease-associated variants. It is possible that the observed 379 phenotypic similarity in partners may be caused by mechanisms outside of assortative mating, including 380 partner convergence⁷⁶ or, in disease cohorts, caregiver burden on parents of affected children⁷⁷. 381 However, we find it unlikely that these mechanisms could account for all observed partner similarity for 382 three key reasons. Firstly, previous studies have indicated that convergence has only a modest effect on 383 spousal similarity^{76,78}. Further, of the 27 participants in the 16p12.1 deletion cohort who indicated the 384 age at depression symptom onset, 70% (19/27) began having symptoms before the birth of their first 385 child. Thus, caregiver burden is an unlikely cause of depression in these individuals and, although these 386 data are limited, we expect similar trends for other disorders. Finally, if spousal phenotypic similarity 387 were the result of convergence or caregiver burden, we would not expect to see a correlation in genetic 388 risk between partners. However, as we do see a strong correlation in rare variant burden, we can 389 conclude that active assortment accounts for much of the observed phenotypic similarity between 390 partners.

391 Partner assortment on these phenotypes drives increases in genetic risk alleles across generations 392 in affected individuals⁷⁵, similar to the observed patterns of increasing secondary variant burden that are 393 well documented in cohorts of variably expressive $CNVs^{11,14}$ and are concordant with a "two-hit" 394 mechanism of pathogenicity. Under assortative mating, individuals with similar psychiatric phenotypes 395 but distinct underlying genetic etiologies may preferentially mate and have a child who carries genetic 396 risks from both parents, leading to a compounding of genetic burden over generations. Increased disease

23

397 liability in children resulting from assortative mating has been previously shown^{17,59}, and the 398 implications for this finding in the context of variably expressive rare variants has been previously 399 hypothesized⁷⁹. Here, our analysis provides more evidence to support the relationship between parental 400 assortment on psychiatric phenotypes and compounding genetic burden towards disease severity. 401 Unique combinations of rare variants arising from recent mutations have been identified as a major 402 contributor to disease $80,81$ and assortative mating may drive accumulation of those new combinations. 403 This observation has important implications on the trajectory of individuals within a family carrying a 404 variably expressive variant and provides insights into the genetic "anticipation" observed in these 405 families.

406 We further highlight the role of spousal relatedness towards complex disorders, showing that 407 spousal kinship acts as a risk factor for variably expressive variants. Long stretches of homozygosity h 408 have previously been implicated in neurodevelopmental disorders^{68,69} and we show here that parental 409 relatedness increases genome-wide homozygosity and, likely through this mechanism, acts as a risk 410 factor for neurodevelopmental disease. Increases in spousal kinship are often due to population 411 stratification⁷⁶, which has heretofore been an underexplored risk factor for neurodevelopmental 412 disorders and may represent an exciting new avenue for further research.

413 While these results have interesting implications for our understanding of disease pathogenicity, 414 our study has some limitations. We restricted our analysis of phenotypic assortment to only a subset of 415 distinct phenotypes, and while we attempted to control for comorbidities that could inflate correlation 416 estimates, it is likely that some cross-disorder contamination remains. Further, all cohorts assessed here 417 were primarily of European descent and further research is needed to understand how assortment and 418 partner similarity may vary across racial and ethnic groups, particularly for disease-associated rare 419 variants. This may be particularly relevant in the context of isolated populations or those practicing 420 endogamy, who, due to their unique recent genetic history, may have a higher load of both parental

24

- 421 relatedness and rare variant burden^{82,83}. Further research is required to examine the genetic architecture
- 422 in these populations and how these changes in architecture may impact disease risk.
- 423 In summary, we provide evidence for assortative mating on neuropsychiatric disorders,
- 424 particularly in parents of children with neurodevelopmental phenotypes. We show patterns of rare
- 425 variant burden similarities between spouses and highlight compounding of rare variant burden over
- 426 generations resulting from phenotypic assortment. We also highlight increased spousal kinship as a risk
- 427 factor for neurodevelopmental disorders through the unmasking of recessive alleles. Overall, our results
- 428 highlight the importance of assessing parental history of neuropsychiatric disease and parental
- 429 relatedness for more accurate assessment of neuropsychiatric disease risk in children and counseling of
- 430 families carrying variably expressive variants.
- 431

432 **ACKNOWLEDGEMENTS**

433 This work was supported by grants T32GM102057 to Miss Corrine Smolen and NS122398 and

434 GM121907 to Dr. Santhosh Girirajan from the National Institutes of Health. Dr. Charles Schwartz was

435 supported, in part, by a grant from the South Carolina Department of Disabilities and Special Needs. Dr.

436 Corrado Romano was supported by the Italian Ministry of Health-Ricerca Corrente 2022.

437

438 We are grateful to the families in the 16p12.1 deletion cohort who participated in this study. We are

439 grateful to all the families in SPARK, the SPARK clinical sites and SPARK staff. We are also grateful

440 to all of the families at the participating Simons Simplex Collection (SSC) sites, as well as the principal

- 441 investigators (A. Beaudet, R. Bernier, J. Constantino, E. Cook, E. Fombonne, D. Geschwind, R. Goin-
- 442 Kochel, E. Hanson, D. Grice, A. Klin, D. Ledbetter, C. Lord, C. Martin, D. Martin, R. Maxim, J. Miles,
- 443 O. Ousley, K. Pelphrey, B. Peterson, J. Piggot, C. Saulnier, M. State, W. Stone, J. Sutcliffe, C. Walsh, Z.
- 444 Warren, E. Wijsman). We appreciate gaining access to genetic and phenotypic data on SFARI Base.

- 445 Approved researchers can obtain the SSC and SPARK datasets described in this study by applying at
- 446 https://base.sfari.org. This research has been conducted using data from UK Biobank, a major
- 447 biomedical database. More information about UK Biobank is available at https://www.ukbiobank.ac.uk/. 448

449 **DECLARATIONS OF INTERESTS**

450 Dr. Santhosh Girirajan reports grants from the National Institutes of Health outside the submitted work.

- 451 Drs. Lisa Dyer and Jane Juusola are employees of GeneDx, LLC. All other authors report no financial
- 452 relationships with commercial interests.
- 453

454 **DATA AND CODE AVAILABILITY**

455 Microarray and genome sequencing data from participants in the 16p12.1 deletion cohort who consented

- 456 to having their information shared anonymously will be made available at NCBI dbGaP study accession
- 457 phs00245. Phenotype and genetic data from the SPARK and SSC autism and UK Biobank cohorts
- 458 through the cohorts' data portals: SFARI base (https://base.sfari.org) and UK Biobank database
- 459 (https://www.ukbiobank.ac.uk), respectively. All code for analysis will be available at GitHub
- 460 (https://github.com/girirajanlab/Assortative_mating_project).

461 **REFERENCES**

- 462 1. Antaki, D. *et al.* A phenotypic spectrum of autism is attributable to the combined effects of rare
- 463 variants, polygenic risk and sex. *Nat Genet* (2022) doi:10.1038/s41588-022-01064-5.
- 464 2. Havdahl, A. *et al.* Genetic contributions to autism spectrum disorder. *Psychol Med* **51**, 2260–2273
- 465 (2021).
- 466 3. Karayiorgou, M. *et al.* Schizophrenia susceptibility associated with interstitial deletions of
- 467 chromosome 22q11. *Proc Natl Acad Sci U S A* **92**, 7612–7616 (1995).
- 468 4. Kvarnung, M. & Nordgren, A. Intellectual Disability & Rare Disorders: A Diagnostic Challenge.
- 469 *Adv Exp Med Biol* **1031**, 39–54 (2017).
- 470 5. Marshall, C. R. *et al.* Contribution of copy number variants to schizophrenia from a genome-wide
- 471 study of 41,321 subjects. *Nat Genet* **49**, 27–35 (2017).
- 472 6. Rein, B. & Yan, Z. 16p11.2 Copy Number Variations and Neurodevelopmental Disorders. *Trends* 473 *Neurosci* **43**, 886–901 (2020).
- 474 7. Singh, T. *et al.* Rare coding variants in ten genes confer substantial risk for schizophrenia. *Nature* 475 **604**, 509–516 (2022).
- 476 8. Jensen, M. & Girirajan, S. An interaction-based model for neuropsychiatric features of copy-number 477 variants. *PLoS Genet* **15**, e1007879 (2019).
- 478 9. Moreno-De-Luca, A. *et al.* Developmental brain dysfunction: revival and expansion of old concepts 479 based on new genetic evidence. *Lancet Neurol* **12**, 406–414 (2013).
- 480 10. Schaaf, C. P. *et al.* Phenotypic spectrum and genotype-phenotype correlations of NRXN1 exon
- 481 deletions. *Eur J Hum Genet* **20**, 1240–1247 (2012).
- 482 11. Girirajan, S. *et al.* A recurrent 16p12.1 microdeletion supports a two-hit model for severe
- 483 developmental delay. *Nat Genet* **42**, 203–209 (2010).
- 484 12. Girirajan, S. & Eichler, E. E. Phenotypic variability and genetic susceptibility to genomic disorders.
- 485 *Hum Mol Genet* **19**, R176-187 (2010).

- 486 13. Leblond, C. S. *et al.* Genetic and functional analyses of SHANK2 mutations suggest a multiple hit
- 487 model of autism spectrum disorders. *PLoS Genet* **8**, e1002521 (2012).
- 488 14. Pizzo, L. *et al.* Rare variants in the genetic background modulate cognitive and developmental
- 489 phenotypes in individuals carrying disease-associated variants. *Genet Med* **21**, 816–825 (2019).
- 490 15. Girirajan, S. *et al.* Phenotypic heterogeneity of genomic disorders and rare copy-number variants. *N*
- 491 *Engl J Med* **367**, 1321–1331 (2012).
- 492 16. Jensen, M. *et al.* Combinatorial patterns of gene expression changes contribute to variable
- 493 expressivity of the developmental delay-associated 16p12.1 deletion. *Genome Med* **13**, 163 (2021).
- 494 17. Nordsletten, A. E. *et al.* Evaluating the Impact of Nonrandom Mating: Psychiatric Outcomes Among
- 495 the Offspring of Pairs Diagnosed With Schizophrenia and Bipolar Disorder. *Biol Psychiatry* **87**,
- 496 253–262 (2020).
- 497 18. Rasic, D., Hajek, T., Alda, M. & Uher, R. Risk of mental illness in offspring of parents with
- 498 schizophrenia, bipolar disorder, and major depressive disorder: a meta-analysis of family high-risk

499 studies. *Schizophr Bull* **40**, 28–38 (2014).

- 500 19. Sullivan, P. F. *et al.* Family history of schizophrenia and bipolar disorder as risk factors for autism. 501 *Arch Gen Psychiatry* **69**, 1099–1103 (2012).
- 502 20. Jensen, M. & Girirajan, S. Mapping a shared genetic basis for neurodevelopmental disorders. 503 *Genome Med* **9**, 109 (2017).
- 504 21. Fischbach, G. D. & Lord, C. The Simons Simplex Collection: a resource for identification of autism 505 genetic risk factors. *Neuron* **68**, 192–195 (2010).
- 506 22. SPARK Consortium. SPARK: A US Cohort of 50,000 Families to Accelerate Autism Research.
- 507 *Neuron* **97**, 488–493 (2018).
- 508 23. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 509 203–209 (2018).

- 510 24. Howe, L. J. *et al.* Genetic evidence for assortative mating on alcohol consumption in the UK
- 511 Biobank. *Nat Commun* **10**, 5039 (2019).
- 512 25. Retterer, K. *et al.* Assessing copy number from exome sequencing and exome array CGH based on
- 513 CNV spectrum in a large clinical cohort. *Genet Med* **17**, 623–629 (2015).
- 514 26. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078–2079
- 515 (2009).
- 516 27. McKenna, A. *et al.* The Genome Analysis Toolkit: a MapReduce framework for analyzing next-
- 517 generation DNA sequencing data. *Genome Res* **20**, 1297–1303 (2010).
- 518 28. Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *Gigascience* **10**, giab008 (2021).
- 519 29. Lek, M. *et al.* Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**, 285–291
- 520 (2016).
- 521 30. Pedersen, B. S., Layer, R. M. & Quinlan, A. R. Vcfanno: fast, flexible annotation of genetic 522 variants. *Genome Biol* **17**, 118 (2016).
- 523 31. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from 524 high-throughput sequencing data. *Nucleic Acids Res* **38**, e164 (2010).
- 525 32. Frankish, A. *et al.* GENCODE 2021. *Nucleic Acids Res* **49**, D916–D923 (2021).
- 526 33. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting the
- 527 deleteriousness of variants throughout the human genome. *Nucleic Acids Res* **47**, D886–D894 528 (2019).
- 529 34. Abrahams, B. S. *et al.* SFARI Gene 2.0: a community-driven knowledgebase for the autism 530 spectrum disorders (ASDs). *Mol Autism* **4**, 36 (2013).
- 531 35. Grove, J. *et al.* Identification of common genetic risk variants for autism spectrum disorder. *Nat* 532 *Genet* **51**, 431–444 (2019).
- 533 36. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage
- 534 analyses. *Am J Hum Genet* **81**, 559–575 (2007).

- 535 37. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat Genet* **48**, 1284–1287
- 536 (2016).
- 537 38. International HapMap 3 Consortium *et al.* Integrating common and rare genetic variation in diverse 538 human populations. *Nature* **467**, 52–58 (2010).
- 539 39. Privé, F., Arbel, J. & Vilhjálmsson, B. J. LDpred2: better, faster, stronger. *Bioinformatics* **36**, 5424–
- 540 5431 (2021).
- 541 40. Constantino, J. N. & Gruber, C. P. *Social responsiveness scale second edition (SRS-2): Manual*.
- 542 (Western Psychological Services (WPS), 2012).
- 543 41. Hurley, R. S. E., Losh, M., Parlier, M., Reznick, J. S. & Piven, J. The broad autism phenotype
- 544 questionnaire. *J Autism Dev Disord* **37**, 1679–1690 (2007).
- 545 42. Price, A. L. *et al.* Long-range LD can confound genome scans in admixed populations. *Am J Hum* 546 *Genet* **83**, 132–135; author reply 135-139 (2008).
- 547 43. Raj, A., Stephens, M. & Pritchard, J. K. fastSTRUCTURE: variational inference of population 548 structure in large SNP data sets. *Genetics* **197**, 573–589 (2014).
- 549 44. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies.
- 550 *Bioinformatics* **26**, 2867–2873 (2010).
- 551 45. Makowski, D., Ben-Shachar, M., Patil, I. & Lüdecke, D. Methods and Algorithms for Correlation 552 Analysis in R. *JOSS* **5**, 2306 (2020).
- 553 46. Virtanen, P. *et al.* SciPy 1.0: Fundamental Algorithms for Scientific Computing in Python. *Nature*
- 554 *Methods* **17**, 261–272 (2020).
- 555 47. Dean, K. *et al.* Full spectrum of psychiatric outcomes among offspring with parental history of 556 mental disorder. *Arch Gen Psychiatry* **67**, 822–829 (2010).
- 557 48. Stapp, E. K., Mendelson, T., Merikangas, K. R. & Wilcox, H. C. Parental bipolar disorder, family
- 558 environment, and offspring psychiatric disorders: A systematic review. *J Affect Disord* **268**, 69–81
- 559 (2020).

- 560 49. Bodfish, J. W., Symons, F. J., Parker, D. E. & Lewis, M. H. Repetitive behavior scale–revised.
- 561 *Journal of Autism and Developmental Disorders* (1999).
- 562 50. Achenbach, T. M. The Child Behavior Checklist and related instruments. in *The use of*
- 563 *psychological testing for treatment planning and outcomes assessment, 2nd ed.* 429–466 (Lawrence
- 564 Erlbaum Associates Publishers, 1999).
- 565 51. Agrawal, A. *et al.* Assortative mating for cigarette smoking and for alcohol consumption in female
- 566 Australian twins and their spouses. *Behav Genet* **36**, 553–566 (2006).
- 567 52. Grant, J. D. *et al.* Spousal concordance for alcohol dependence: evidence for assortative mating or
- 568 spousal interaction effects? *Alcohol Clin Exp Res* **31**, 717–728 (2007).
- 569 53. Greve, A. N. *et al.* A Nationwide Cohort Study of Nonrandom Mating in Schizophrenia and Bipolar
- 570 Disorder. *Schizophr Bull* **47**, 1342–1350 (2021).
- 571 54. Nordsletten, A. E. *et al.* Patterns of Nonrandom Mating Within and Across 11 Major Psychiatric 572 Disorders. *JAMA Psychiatry* **73**, 354–361 (2016).
- 573 55. Plomin, R. & Deary, I. J. Genetics and intelligence differences: five special findings. *Mol Psychiatry*
- 574 **20**, 98–108 (2015).
- 575 56. Boomsma, D. I. *et al.* Genetic epidemiology of attention deficit hyperactivity disorder (ADHD
- 576 index) in adults. *PLoS One* **5**, e10621 (2010).
- 577 57. Krueger, R. F., Moffitt, T. E., Caspi, A., Bleske, A. & Silva, P. A. Assortative mating for antisocial
- 578 behavior: developmental and methodological implications. *Behav Genet* **28**, 173–186 (1998).
- 579 58. Mathews, C. A. & Reus, V. I. Assortative mating in the affective disorders: a systematic review and 580 meta-analysis. *Compr Psychiatry* **42**, 257–262 (2001).
- 581 59. Gottesman, I. I., Laursen, T. M., Bertelsen, A. & Mortensen, P. B. Severe mental disorders in
- 582 offspring with 2 psychiatrically ill parents. *Arch Gen Psychiatry* **67**, 252–257 (2010).
- 583 60. Yengo, L. *et al.* Imprint of assortative mating on the human genome. *Nat Hum Behav* **2**, 948–954
- 584 (2018).

- 585 61. Robinson, M. R. *et al.* Genetic evidence of assortative mating in humans. *Nat Hum Behav* **1**, 0016
- 586 (2017).
- 587 62. Torvik, F. A. *et al.* Modeling assortative mating and genetic similarities between partners, siblings, 588 and in-laws. *Nat Commun* **13**, 1108 (2022).
- 589 63. Cheng, S. *et al.* Exome-wide screening identifies novel rare risk variants for major depression
- 590 disorder. *Mol Psychiatry* **27**, 3069–3074 (2022).
- 591 64. Smoller, J. W. The Genetics of Stress-Related Disorders: PTSD, Depression, and Anxiety Disorders.
- 592 *Neuropsychopharmacology* **41**, 297–319 (2016).
- 593 65. Fisher, R. A. XV.—The Correlation between Relatives on the Supposition of Mendelian Inheritance.
- 594 *Earth and Environmental Science Transactions of The Royal Society of Edinburgh* **52**, 399–433
- 595 (1919).
- 596 66. Alkuraya, F. S. Homozygosity mapping: one more tool in the clinical geneticist's toolbox. *Genet* 597 *Med* **12**, 236–239 (2010).
- 598 67. Ceballos, F. C., Joshi, P. K., Clark, D. W., Ramsay, M. & Wilson, J. F. Runs of homozygosity:
- 599 windows into population history and trait architecture. *Nat Rev Genet* **19**, 220–234 (2018).
- 600 68. Gamsiz, E. D. *et al.* Intellectual disability is associated with increased runs of homozygosity in
- 601 simplex autism. *Am J Hum Genet* **93**, 103–109 (2013).
- 602 69. Lencz, T. *et al.* Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. *Proc* 603 *Natl Acad Sci U S A* **104**, 19942–19947 (2007).
- 604 70. Rosenfeld, J. A., Coe, B. P., Eichler, E. E., Cuckle, H. & Shaffer, L. G. Estimates of penetrance for 605 recurrent pathogenic copy-number variations. *Genet Med* **15**, 478–481 (2013).
- 606 71. Douard, E. *et al.* Effect Sizes of Deletions and Duplications on Autism Risk Across the Genome.
- 607 *AJP* **178**, 87–98 (2021).
- 608 72. Falconer, D. S. Inheritance of liability to certain diseases estimated from incidence among relatives.
- 609 *Ann. Hum. Genet.* **29**, 51–76 (1965).

- 610 73. Bergen, S. E. *et al.* Joint Contributions of Rare Copy Number Variants and Common SNPs to Risk
- 611 for Schizophrenia. *Am J Psychiatry* **176**, 29–35 (2019).
- 612 74. Martin, J., O'Donovan, M. C., Thapar, A., Langley, K. & Williams, N. The relative contribution of
- 613 common and rare genetic variants to ADHD. *Transl Psychiatry* **5**, e506 (2015).
- 614 75. Plomin, R., Krapohl, E. & O'Reilly, P. F. Assortative Mating-A Missing Piece in the Jigsaw of
- 615 Psychiatric Genetics. *JAMA Psychiatry* **73**, 323–324 (2016).
- 616 76. Versluys, T. M. M., Flintham, E. O., Mas-Sandoval, A. & Savolainen, V. Why do we pick similar
- 617 mates, or do we? *Biol Lett* **17**, 20210463 (2021).
- 618 77. Turnage, D. & Conner, N. Quality of life of parents of children with Autism Spectrum Disorder: An
- 619 integrative literature review. *J Spec Pediatr Nurs* **27**, e12391 (2022).
- 620 78. Tambs, K. & Moum, T. No Large Convergence during Marriage for Health, Lifestyle, and
- 621 Personality in a Large Sample of Norwegian Spouses. *Journal of Marriage and the Family* **54**, 957 622 (1992).
- 623 79. Costain, G. *et al.* Adult neuropsychiatric expression and familial segregation of 2q13 duplications.
- 624 *Am J Med Genet B Neuropsychiatr Genet* **165B**, 337–344 (2014).
- 625 80. Lupski, J. R., Belmont, J. W., Boerwinkle, E. & Gibbs, R. A. Clan genomics and the complex
- 626 architecture of human disease. *Cell* **147**, 32–43 (2011).
- 627 81. Pounraja, V. & Girirajan, S. A general framework for identifying oligogenic combinations of rare 628 variants in complex disorders. *Genome Res* **32**, 904–915 (2022).
- 629 82. Bittles, A. H. Endogamy, consanguinity and community disease profiles. *Community Genet* **8**, 17– 630 20 (2005).
- 631 83. Halachev, M. *et al.* Increased ultra-rare variant load in an isolated Scottish population impacts
- 632 exonic and regulatory regions. *PLoS Genet* **15**, e1008480 (2019).
- 633
- 634